Back to articles

Aclidinium not shown to increase CV risk in patients with COPD


Use of aclidinium bromide (Tudorza Pressair—Circassia) in patients with chronic obstructive pulmonary disease (COPD) and established cardiovascular (CV) disease or CV risk factors was noninferior to placebo for risk of major adverse cardiovascular events (MACE) over 3 years. It also decreased the rate of moderate to severe COPD exacerbations over the first year, according to results from the ASCENT-COPD trial published in JAMA.